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Abstract
Exclusive enteral nutrition (EEN) has proven to be a highly effective  treatment 
option in inducing remission in active Crohn’s disease (CD) in the paediatric 
population. In adults with CD, the results of meta-analyses demonstrated that 
therapy with corticosteroids was more effective in comparison with EEN. The 
most important limitation of the success of EEN treatment is patients’ compliance. 
Exclusivity of enteral nutrition and its substantial impact on the quality of life 
are the main reasons why EEN is not acceptable to many patients. Therefore, the 
treatment with partial enteral nutrition (PEN), where patients are allowed to eat 
some ordinary food besides enteral formulas, is becoming an important treatment 
option, not only in inducing, but also in maintaining remission in CD. However, 
strong evidence on the efficacy of PEN for induction and maintenance of CD 
remission is still lacking. Due to the excellent safety profile of the treatment with 
enteral nutrition in comparison with other treatment modalities, further well-
designed, randomised, controlled studies are necessary to elucidate the exact role 
of PEN in inducing and maintaining of remission in CD patients. Herein, the most 
relevant studies on the efficacy and the role of PEN in active and quiescent CD are 
reviewed.
Keywords: Crohn’s disease, enteral nutrition, partial enteral nutrition, children, 
adults
1. Introduction
Crohn’s disease (CD) is a life-long immune-mediated inflammatory disease 
which may affect any part of the gastrointestinal tract. The aetiology of the disease 
is multifactorial and complex, with genetic and environmental factors involved. It 
is widely accepted that inappropriate response of the innate and adaptive immune 
system to the altered composition of the indigenous intestinal microbiota plays 
crucial role in the pathogenesis. Both the development and treatment of the disease 
may therefore be influenced by different factors that can affect the composition of 
the intestinal microbiota, the permeability of the epithelial barrier, or the function-
ing of the gut immune system. Each of these factors can be significantly affected by 
nutrition. Epidemiological studies have shown that a diet containing large quanti-
ties of red and processed meat, animal fat, and refined sugars is associated with an 
increased risk, and a diet containing large quantities of fruits and vegetables with a 
reduced risk for CD development [1–4].
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Therefore, the possibilities of treating CD with nutritional therapy are par-
ticularly interesting. Close partnership between the patients, gastroenterologist 
and dietitian is necessary when utilising nutritional therapy to treat CD. Dietitian 
provides support for dietary changes and asses the actual nutrient intake, patient’s 
nutritional status, and discuss the role of enteral nutrition as the treatment option. 
Dietitian should be included in patient’s treatment from diagnosis onwards. The 
ultimate goal of CD treatment is to induce and maintain clinical remission and 
mucosal healing with treatment modalities with least adverse effects [5]. Compared 
to other treatments such as corticosteroids (CS), immunomodulators and biologic 
drugs, nutritional therapy has an excellent safety profile, presenting with signifi-
cantly less adverse effects compared to any other type of treatment. Many adverse 
effects of immunosuppressive drugs (thiopurines, methotrexate) and biologi-
cal drugs, especially the increased risk of infections and malignancy, have been 
reported and are of major concern [6–9].
Since the discovery that exclusive enteral nutrition (EEN) that provides 
adequate nutritional intake of all macro- and micronutrients over a sufficiently 
long period can not only improve the nutritional status of patients but also allevi-
ate inflammation, such treatment has been extensively studied. There is strong 
evidence that EEN is as effective as CS in inducing remission in patients with CD. 
In paediatric patients, when it comes to the induction of mucosal healing, EEN 
seems to be even more effective then CS [10–15]. EEN was also found to be able to 
promote transmural healing [16, 17]. There are currently many different enteral 
formulas available on the market. Some are elemental, semi-elemental and others 
polymeric. They differ in flavour, energy density, osmolarity, content of dietary 
fibre and some other nutrients but they all provide sufficient energy and essential 
nutrients intake.
Patients with CD are often malnourished at the time of diagnosis and growth 
retardation is frequently present in paediatric patients [18–20], so a positive 
effect on nutritional status and growth represents an important additional 
benefit of EEN [21]. Therefore, consensus guidelines of the European Society 
of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the 
European Crohn’s Colitis Organisation (ECCO) recommends EEN as a first-line 
therapy in all children with active CD, including those with colonic involve-
ment [22]. Although, based on some initial studies, EEN had been shown to 
be as effective as CS for induction of remission also in adult patients with CD 
[23–27], subsequent studies did not confirmed this, and their meta-analyses 
demonstrated that CS were more effective treatment option in adult CD patients 
[13, 14, 28–31].
The reason for different efficacy of EEN in paediatric and adult CD popula-
tions is not completely understood. It may be due to longer disease course, higher 
prevalence of more aggressive phenotypes and more permanent structural changes 
of the bowel in adults. In addition, EEN is probably not so strictly adhered to in 
adult patients, when compared to children, who are usually under supervision 
from their parents. Children and especially adolescents are more motivated to 
achieve remission through the use of EEN, as most of them decline CS treat-
ment due to appearance related side effects such as facies lunata, acne vulgaris 
and increased hairiness [5, 22]. The difference may also be due to the lack of 
well-designed randomised controlled studies in adult CD population. It has been 
noted, that the conclusions of the meta-analyses on the superior efficacy of CS 
in adults were mainly based on an intention to treat analyses, while when only 
results of the patients who strictly adhered to EEN protocols were analysed, the 
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remission rates were comparable to those receiving CS [32]. Anyway, except for 
Japan, induction therapy with EEN is not common in adult patients with active 
CD. Japanese guidelines recommend EEN as one of the treatment options for 
active CD in adults [33], since a Japanese study reported that elemental EEN had 
a higher rate of induction of remission in CD patients compared with CS and has 
improved luminal lesions [34]. ECCO guidelines for medical management of adult 
CD from 2016 recommended the use of EEN as an adjunctive treatment to improve 
nutritional status and in patients who decline other drug therapy [35], while in the 
most recent edition of this guidelines from 2019 EEN is not mentioned at all [36]. 
Recent guidelines of the European Society for Clinical Nutrition and Metabolism 
(ESPEN) directly recommends EEN as a first line of treatment only for children 
and adolescents, while an option to use EEN in selected cases of adults is men-
tioned only in fine print [37].
Despite the strong evidence of EEN efficiency in paediatric and potentially in 
adult CD patients as well and its better impact on mucosal healing in comparison 
with CS, EEN is not popular in many parts of the world. Its major disadvantage is 
the need to consume exclusively enteral formulas, while avoiding all other foods 
for a long period, usually 6–8 weeks. This has a substantial impact on the quality 
of life and is unacceptable for many patients. Although all formulas used for EEN 
are designed for oral use, many patients (although there are significant differences 
between parts of the world and between children and adults) accept them so poorly 
that they must be administered via a nasogastric tube. To overcome this main 
constraint, the idea of the use of partial enteral nutrition (PEN) instead of EEN 
has emerged. Compliance and adherence to enteral nutrition would likely be much 
better if patients could consume some ordinary food besides the enteral formula, 
either unrestricted or in a form of specified elimination diets (ED). The ideal 
candidates for PEN are therefore all patients who are not adherent to EEN and those 
who do not want to receive CS due to their several side effects. In addition, there is a 
growing body of research addressing the possibility of nutritional treatment of CD 
with diets containing only a limited selection of ordinary foods without the addi-
tion of enteral formulas. Although there are many such diets, objective data on their 
effectiveness are very limited.
Therefore, we limited our systematic review to the efficacy of therapeutic 
approaches using PEN in combination with either unrestricted or specified ED for 
induction of CD remission in adults and children, while other nutritional treatment 
options are presented only in the outline of the discussion.
2. Literature search
A systematic literature search was conducted using PubMed Library on April 3, 
2020. The following user query was used: (“crohn disease”[MeSH Terms] OR 
“crohn”[Title/Abstract] OR “crohn disease”[Title/Abstract] OR “crohn’s”[Title/
Abstract] OR “crohn’s disease”[Title/Abstract]) AND (“enteral nutrition”[MeSH 
Terms] OR “enteral”[Title/Abstract] OR “enteral nutrition”[Title/Abstract]) 
NOT “parenteral”[Title/Abstract] NOT “exclusive”[Title/Abstract] AND 
“english”[language].
Based on these criteria, from 399 publications identified in PubMed database 
using these terms, 13 key articles were selected for further analysis, first identified 
study being published in 1996 (only 3 articles were published before 2004). All 
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RCT: randomised controlled trial; NS: not significant; EAR: Estimated Average Requirement; PEN: partial enteral nutrition; Non-PEN: without PEN; NT: no treatment; ED: elemental diet; PD: polymeric 
diet; HED: half elemental diet; MP: mercaptopurine; EEN/PEN: PEN after EEN treatment; CS/NT: no treatment (normal diet) after CS; AZA: azathioprine; CG: control group; IFX: infliximab; 5-ASA: 
5-aminosalicyilic acid.
Table 1. 
Summary of key studies on efficacy of partial enteral nutrition (PEN) in maintaining Crohn’s disease (CD) remission.
7
Partial Enteral Nutrition in Crohn’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.95385
3. Results
3.1  Partial enteral nutrition (PEN) for induction of remission in active Chron’s 
disease (CD)
Through a systematic search, we identified 8 original articles on the use of PEN 
for induction of remission in active CD (Table 1). Of these, 5 papers presented 
the results of prospective controlled trials, 2 randomised and 3 non-randomised, 
while 3 papers described retrospective analyses of medical records of patient series. 
Beside to the basic methodology, research differed most in how much of a daily 
energy requirements patient received in the form of PEN and what they enjoyed as 
the rest of their daily energy requirements, unrestricted diet or special ED. In addi-
tion, we found 3 original studies using PEN simultaneously with different medical 
therapies for induction of remission [49–51]. It was impossible to determine how 
much of the effect on a disease activity could be attributed to the PEN itself from 
the result of these studies, so we did not include them in this review.
In 2006, Johnson et al. [52] published the results of the first prospective ran-
domised controlled trial on the efficacy of PEN compared with EEN in inducing 
remission in active CD. Fifty children with active CD were randomised into two 
groups. In the “PEN group”, children received 50% of their daily energy require-
ments from the elemental formula and 50% from an unrestricted diet. The control 
group consisted of children, treated with EEN, with 100% of their daily energy 
requirements provided from the elemental enteral formula. The remission rate after 
a 6 week-treatment period was significantly higher in EEN group (10/24, 42%) 
compared to the PEN group (4/26, 15%) (P = 0.035), pointing to a low efficacy of 
PEN [52]. Of note, the intention to treat remission rate in this study using elemental 
enteral formula was surprisingly low, even for EEN control group, in compare to 
majority of other studies.
In a retrospective cohort study by Gupta et al. [53] from the Children’s Hospital 
of Philadelphia (CHOP), the remission and response rates were determined in 43 
children who were treated for active CD with PEN according to the CHOP protocol, 
where all patients received 80–90% of their daily energy requirements from the 
enteral formula (elemental, semi-elemental or polymeric) and the rest from an 
unrestricted diet. This study showed a remission and response rate of 65% and 87%, 
respectively, after a mean treatment period of 2 months (1–4 months) [53]. These 
results are in line with the remission rates of EEN treatment reported from litera-
ture [12, 22, 54, 55]. Additionally, the study protocol with PEN was able to increase 
weight and improve laboratory markers in children with CD. The authors concluded 
that CHOP protocol, that allows patients to consume a small amount of ordinary 
food, has an important positive impact on treatment adherence and on the quality 
of life during the treatment period [53].
In a prospective cohort study, Lee et al. [56] compared clinical outcomes and 
mucosal healing as estimated by faecal calprotectin in 90 children with active CD 
receiving either PEN (n = 16), EEN (n = 22) or anti-tumour necrosis factor (TNF) 
therapy (n = 52) for induction of remission. After an 8-week treatment period, 
clinical response was demonstrated in 64% of patients on PEN, 88% on EEN, and 
84% on anti-TNF (P = 0.08). EEN and anti-TNF were significantly more effective 
in diminishing mucosal inflammation compared to PEN. The reduction of faecal 
calprotectin to ≤250 μg/g was found in 14% of patients on PEN, 45% on EEN, and 
62% on anti-TNF (P < 0.001) [56].
Wall et al. [57] performed a prospective non-randomised study including 38 
adolescent and young adult patients with active CD. All patients were treated with 
EEN for the first two weeks, six (16%) of them discontinued this treatment in a 
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few days because of personal decision or intolerance to polymeric enteral formula. 
After this initial period 21 patients were treated with EEN and 11 patients with 
PEN allowing one meal of ordinary food per day for another 6 weeks. Seven (33%) 
patients from EEN group and 2 (18%) patients from PEN did not complete the 
treatment, predominantly because of complications and worsening of disease. 
There was no significant difference between the groups (P = 0.5). During the initial 
two weeks of treatment with EEN, clinical Harvey–Bradshaw Index (HBI), serum 
C-reactive protein (CRP) and faecal calprotectin concentrations significantly 
decreased (P = 0.003; P = 0.005, P = 0.028). The authors observed further clinical 
improvement in patients who continued with EEN with significant decrease of HBI 
(P = 0.031), while markers of inflammation remained stable. In the PEN group, 
clinical condition and markers of inflammation did not significantly change during 
6-week therapy. The authors concluded that there were no significant differences in 
disease activity or inflammatory markers at week 8 between patients who used EEN 
for 8 weeks compared with patients who used 2 weeks of EEN followed by 6 weeks 
of PEN [57].
In contrast with aforementioned studies allowing to eat a certain proportion of 
unrestricted ordinary food along with enteral formulas, other researchers combined 
PEN with specially designed diets.
A group of investigators from Israel led by Arie Levine developed a special diet 
named Crohn’s disease elimination diet (CDED), based on the exclusion of dietary 
components hypothesised to affect either the microbiome, intestinal permeability, 
or innate immune system involved in CD pathogenesis. It excludes animal fats, milk 
and dairy, gluten and all processed and canned foods that contain additives (espe-
cially emulsifiers and maltodextrin) [58–60]. According to the authors’ hypothesis, 
the major mechanism leading to response to EEN, is the exclusion of specific delete-
rious dietary factors which may impair the barrier function of the intestinal mucus 
layer and epithelium that allows adherence and invasion of non-pathogenic bacteria 
or bacterial antigens. The adherence of bacteria to the intestinal epithelium, their 
penetration and replication within the cells of the innate immune system such as 
epithelial cells, macrophages and dendritic cells can lead to continuous triggering of 
the adaptive immune system and therefore to the chronic inflammation [59, 61].
In 2014 the group published a retrospective report on cohort of children 
(n = 34) and young adults (n = 13) with active mild to moderate luminal CD who 
had been treated with their PEN protocol for 12 weeks. The protocol consisted of 
two stages. During the first 6 weeks, CDED was more restrictive and 50% of the 
daily energy requirements was provided in the form of polymeric enteral formula. 
In the second 6-week period, polymeric enteral formula was continued to supply 
only 25% of daily energy requirements, while small amounts of whole grain bread, 
and free intake of nuts, fruits, and vegetables were allowed. By week 6, a remis-
sion and response rate were 70.2% and 78.7%, respectively. The remission rates 
were similar in children and adults. In paediatric patients mean Paediatrics Crohn’s 
Disease Activity Index decreased from 27.7 ± 9.4 to 5.4 ± 8.0 (P < 0.001). Similarly, 
HBI decreased from 6.4 ± 2.7 to 1.9 ± 2.9 in adults (P < 0.001). At week 12, 27/32 
(84%) patients, that were in remission at week 6, were still in remission after the 
step-down phase. Normalisation in CRP was observed in 21/30 (70%) patients. 
Surprisingly, 6/7 (86%) patients who were treated with only CDED, without 
additional enteral formula, achieved remission as well [58].
In another retrospective analysis, same group reported their experience with 
21 patients (11 adults and 10 children) who had lost response to biologic drugs 
despite dose escalation or combination therapy and were treated with PEN by a 
polymeric enteral formula and the CDED, 50% of daily energy requirements from 
each, for the first 6 weeks, followed by 6-week step-down phase as described above. 
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Paediatric patients with severe flares received 2 weeks of EEN followed by PEN 
and CDED. Clinical response was obtained in 19/21 (90.4%) patients, and remis-
sion in 13/21 (62%). Mean HBI decreased from 9.4 ± 4.2 to 2.6 ± 3.8 (P < 0.001). 
Three out of the four (75%) patients who used the CDED alone without any enteral 
formula supplementation, entered clinical remission. Significant decrease in CRP 
(P < 0.001) and increase in albumin concentrations (P < 0.005) were observed. 
The authors concluded that dietary treatment combining PEN and CDED may be a 
useful salvage regimen in CD patients failing biological therapy [62].
In 2019, Levine et al. [63] published the results of the multicentre prospective 
randomised controlled trial comparing the efficacy of standard EEN with CDED 
coupled with PEN for the induction of remission of CD. Seventy-eight children with 
mild to moderate active luminal CD were randomised either to EEN for 6 weeks fol-
lowed by 25% of daily energy requirements intake with PEN and gradual introduc-
tion of ordinary foods during next 6 weeks or to CDED 50% and PEN 50% for the 
first 6 weeks followed by step-down phase CDED 75% (as explained before) with 
PEN 25% for the second 6 weeks. The primary endpoint of the study was patients’ 
tolerance to both treatment regimens. The secondary endpoints were clinical 
response, normalisation of laboratory markers, including calprotectin as a surrogate 
marker for mucosal inflammation and changes in faecal microbiota. The combina-
tion of CDED and PEN was tolerated by significantly more participants (97.5%) 
than EEN (73.6%) (P = 0.002). At week 6, the remission rate in both groups did not 
differ significantly (P = 0.38). Thirty of 40 (75%) patients treated by CDEC and 
PEN achieved remission in compare with 20/38 (59%) treated by EEN. However, at 
week 12, significantly more patients given CDED and PEN group (75.6%) were in 
remission compared with children given EEN and then PEN without dietary restric-
tions (45.1%) (P = 0.01) [63].
Recently, Urlep et al. [64] published a prospective cohort study on efficacy of 
PEN combined with ED, a diet resembling CDED and based on basic foods, com-
pared with EEN for inducing a remission in children with active CD. Twenty-five 
patients were allocated to a 6-week nutritional therapy with either EEN or PEN 
combined with one meal per day consisted of food from ED (approximately 25% of 
daily energy requirements). In addition to clinical evaluation and laboratory tests, 
ileocolonoscopy was performed before and after 6 weeks of treatment to directly 
assess the mucosal inflammation by using Simple Endoscopic Score (SES-CD). 
Clinical remission rates were similar in EEN and PEN with ED group (69,2% and 
75%, respectively; P = 0.999). The endoscopic remission rates were 45.5% in both 
groups, and mucosal healing rates were also 45.5% in EEN group and 27.3% in 
PEN with ED group (P = 0.659). The study revealed that PEN in combination with 
relatively easy-to-keep ED was as effective as EEN for induction of both clinical 
and endoscopic remission [64]. However, current ECCO/ESPGHAN guidelines on 
medical management of paediatric CD do not recommend using PEN for the induc-
tion of remission [22].
3.2  Partial enteral nutrition (PEN) as maintenance therapy in Chron’s  
disease (CD)
Summary of key studies on efficacy of PEN in maintaining CD remission in 
adult and paediatric CD patients is presented in Table 1.
3.2.1 PEN for maintenance therapy in adult CD
Already, in the year 1983, Harries et al. [65] reported a beneficial effect of 
additional enteral supplementation on the maintenance of CD remission. They 
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conducted a controlled cross-over study in a cohort of 28 malnourished adult 
CD patients. For a two-month period (control period) the patients were on an 
unrestricted diet and for the next two-month period they received supplementary 
polymeric enteral formula (treatment period). The study demonstrated that the 
addition of enteral formula had a beneficial effect not only on the nutritional status, 
but also on the disease activity [65].
Ten years later, Hirakawa et al. [66] conducted a prospective controlled study in 
61 CD patients who achieved remission with EEN. They were divided into 4 groups 
and followed-up for 1, 2 and 4 years. For maintenance of remission the first group 
of patients was receiving PEN in a form of elemental enteral formula in addition 
to their unrestricted diet. In the second group the same nutritional regimen was 
combined with standard medications. In the third group, only medical therapy 
was used, while the fourth group stayed on an unrestricted diet and without any 
medicines. The cumulative remission rates after 1, 2, and 4 years were significantly 
better in the elemental hyperalimentation group, compared with all other groups. 
It was concluded, that therapy with enteral nutrition has a role not only in inducing 
remission, but also for the maintenance of remission in CD patients [66].
In a non-randomised cohort study by Verma et al. [38], PEN was found to 
be more effective than an unrestricted diet for remission maintenance at 1-year 
follow-up. Adult patients with CD remission (n = 39) were divided into two groups 
according to their choice. Twenty-one out of 39 patients received elemental enteral 
formula (35–50% of daily energy requirements) in addition to their unrestricted 
diet, while the remaining 18 patients chose to have an unrestricted diet. On an 
intention to treat basis, 10 patients (48%) in the first group and 4 patients (22%) in 
the second group were still in remission at 12 months of follow-up (P < 0.000) [38].
In 2001, the same authors studied 33 CD patients with CS-dependent disease 
who were all in remission at the start of the study. They all received enteral formula 
in an amount that provided 35–50% of their daily energy requirements. Patients 
were randomised to receive either an elemental formula (n = 19) or a polymeric for-
mula (n = 14) and were followed up for 12 months. Failure of maintenance therapy 
was defined by an increase in the Crohn’s Disease Activity Index, inability to cessate 
CS or the need for surgery. According to the per-protocol data analysis, the suc-
cess rate of PEN in CS-dependent patients was 14/27 (52%). The response was not 
significantly different between elemental (42%) and polymeric (43%) groups [39].
In a study by Takagi et al. [67], CD patients in remission, achieved with differ-
ent treatment modalities (with CS, 6–8 weeks EEN, surgery, infliximab (IFX)), 
were randomly assigned to two groups. In the ”half elemental diet group« (n = 26) 
patients received half of their daily energy requirements from an elemental enteral 
formula (900–1200 ml daily) and half from an unrestricted diet. Patients in the 
second group (n = 25) were on an unrestricted diet. The relapse rate was signifi-
cantly lower in the half elemental group (9/26; 34.6%) in comparison with the unre-
stricted diet group (16/25; 64%) (P < 0.01), after a mean follow-up of 11.9 months. 
According to the results of this randomised controlled trial, with a low risk of bias, 
PEN seems to be a promising maintenance therapy in CD [67].
In 2006 Esaki et al. [68], conduct a retrospective study which was designed to 
determine risk factors for recurrence of CD under enteral nutrition. They include 
145 patients with CD, who were primarily induced into remission by total parenteral 
nutrition. The patients were classified into two groups: enteral nutrition group 
(n = 98; 1200 kcal/day of enteral nutrition), or non-enteral nutrition group (n = 47; 
< 1200 kcal/day of enteral nutrition) according to the amount of their daily elemen-
tal or polymeric diet. Contributions of enteral nutrition and other clinical variables 
to the recurrence were analysed retrospectively. They conclude that among patients 
with CD under maintenance enteral nutrition, the risk of recurrence differs 
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according to the disease type and the site of involvement. The maintenance treat-
ment by enteral nutrition alone seems insufficient for patients with penetrating 
type or with colonic involvement [68].
In 2007 Yamamoto et al. [40] confirmed the positive impact of PEN in main-
taining CD remission. They conducted a prospective controlled non-randomised 
study in 40 CD patients in remission. Patients in the enteral nutrition group (EN 
group; n = 25) received elemental enteral formula (1200–1800 ml daily) via a 
nasogastric tube at night and a low-fat diet during the day. Non-EN group (n = 20) 
was on an unrestricted diet. On an intention to treat basis, 5 patients (25%) in the 
EN group and 13 patients (65%) in the non-EN group relapsed during the 1-year 
follow-up period (P = 0.03). Furthermore, they demonstrated that the mucosal 
tissue levels of interleukin (IL) 1 beta, IL-6 and TNF-alpha significantly increased 
in the non-EN group during 1 year of follow-up, while the levels of these cytokines 
in the EN group did not change significantly. Similarly, the mucosal inflammation 
seen by ileocolonoscopies was significantly increased in the non-EN group. The 
researchers concluded that PEN is effective in diminishing clinical relapse rates and 
in suppressing cytokine production and mucosal inflammation in CD patients who 
entered clinical remission. Limitations of the study are its relatively small number 
of patients and a non-randomised design. Only patients with good compliance were 
assigned to the EN group, therefore, the bias of the study is high. Nevertheless, this 
study clearly shows that PEN has a positive effect not only on clinical activity but 
also on inflammation of the gut mucosa [40].
In 2009, Takagi et al. [69] investigated the quality of life of patients on PEN for 
maintenance of remission and the medical cost of this treatment regimen. This 
is an extension study of their previous randomised controlled trial [67], which 
showed that quality of life did not significantly differ between the two groups of 
patients; the PEN and the non-PEN group. Interestingly, there was also no statisti-
cally significant difference in the medical costs between these two groups of CD 
patients [69].
Yamamoto et al. [41] conducted a prospective study to examine the efficacy of 
combined PEN and IFX maintenance treatment. Patients who achieved remission 
with IFX and were treated with regular IFX infusions to maintain remission (5 mg/
kg every 8 weeks) were divided into two groups. In the first group patients received 
IFX with concomitant PEN (1200–1500 ml of elemental enteral formula at night 
and low-fat diet during the day). The second group was treated only with mainte-
nance IFX without PEN. Surprisingly, there was no statistically significant differ-
ence observed in remission rates between the two groups at the end of the 56-week 
follow-up (P = 0.51) [41]. However, this study was not randomised, and it involved 
only a small cohort of patients.
On the contrary, other studies demonstrated the beneficial effect of combined 
PEN and IFX maintenance treatment. In a retrospective study by Hirai et al. [42], 
45 patients on maintenance therapy with IFX received concomitant PEN (elemental 
formula; > 900 kcal daily) and 57 patients were administered only IFX without 
PEN. The patients were followed for 544 ± 27 days. The cumulative remission rate 
was significantly higher in the combined PEN and IFX group in comparison to 
the non-combined group (P = 0.009) [42]. The authors hypothesised that PEN 
contributed to the positive effect of maintenance IFX due to its anti-inflammatory 
effect [70–73], the effect on cytokine production and the beneficial effect on gut 
microbiota [74–77].
Similar findings were observed in a multicentric retrospective study by Kamata 
et al. [78]. They found that concomitant PEN (≥ 900 kcal daily) during IFX 
maintenance therapy significantly prolonged the remission period. The group of 
CD patients treated with combined PEN and IFX therapy showed significantly 
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lower cumulative loss of response rate in comparison with the non-combined group 
(P < 0.049). The authors believe that PEN may decrease intestinal inflammation, 
therefore less serum IFX levels may be effective for controlling the disease [78].
In a meta-analysis by Nguyen et al. [79], the effect of concomitant PEN therapy 
with IFX in comparison with IFX monotherapy was assessed for maintenance of CD 
remission. Four studies met the inclusion criteria [41, 42, 80, 81]. In the group of 
patients on the combined PEN and IFX therapy, significantly higher percentage of 
patients (74.5%) remained in clinical remission in comparison with the IFX mono-
therapy group (49.2%) after 1 year of follow-up period (P < 0.01) [79].
Hanai et al. [43] conducted the only adult randomised controlled study com-
paring the efficacy of PEN with 6-mercaptopurine (6-MP) in maintaining CD 
remission. They studied 95 patients with CD in remission who were split into 3 
groups. All patients took 5-aminosalicylic acid (2250–3000 mg per day). In the 
first group (n = 30) they received 6-MP (0.5–1.5 mg/day), in the second group 
(n = 32) they were on PEN (elemental enteral formula; ≥ 900 kcal daily and intake 
of 3.5–4.0 kcal/kg/day from food in line with the recommendation of a qualified 
dietician), in the third group (n = 33) patients received only 5-aminosalicylic acid 
(control group). The percentage of patients who were still in remission after 2 years 
of follow-up were 56.7% (MP group), 46.9% (PEN group) and 21.2% (control 
group), respectively. There was a significantly higher remission rate in the PEN 
group versus the control group (P < 0.034). Furthermore, the remission rates 
between PEN and MP group did not differ significantly (P = 0.273) [43]. Although 
this is a prospective randomised controlled study, its limitation is relatively small 
sample size. Therefore, further larger studies should be conducted to confirm these 
results. As thiopurines are drugs with many side effects [82], results of such studies 
would be desirable to decide upon an appropriate maintenance therapy, that should 
have a high ratio between efficiency and adverse effects.
3.2.2 PEN for maintenance therapy after surgery in CD patients
Some smaller retrospective studies demonstrated that therapy with enteral 
nutrition had reduced relapse rate after surgery in CD patients [83, 84].
In Ikeuchi et al. [83], they examined the effects of postoperative nutritional 
therapy in patients with perforating and non-perforating type of CD. They 
retrospectively reviewed the records for 218 patients who underwent surgical 
interventions for CD between 1974 and 2001. Patients were divided into four 
groups: 92 patients in the non-perforating type group had received an elemental 
diet, 22 patients in the non-perforating type had received an unrestricted diet, 88 
patients in the perforating type had received an elemental diet and 16 patients in 
perforated type had received an unrestricted diet. They conclude that in patients 
with CD postoperative elemental diet and nutritional education is effective in 
reducing the incidence of second resection. It appears that postoperative elemen-
tal diet and nutritional education is more important in patients with perforated 
type CD [83].
Therefore, Yamamoto et al. [85] conducted the first prospective non-randomised 
study in 40 consecutive adult patients after resection for ileal or ileocolonic CD. 
Patients were assigned either to the PEN group (n = 20) or to the control group 
(n = 20) with an unrestricted diet. In the PEN group, patients received elemental 
enteral formula (1200–1800 ml daily) at night, through a nasogastric tube, and a 
low-fat diet during the day. Patients from both groups additionally took 5-aminosali-
cyilic acid 3000 mg daily. Ileocolonoscopy was performed at 6 and 12 months after 
surgery. One patient from the PEN group (5%) and 7 patients (35%) from the con-
trol group relapsed during the 1-year follow-up period (P = 0.048). Furthermore, 
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6 patients (30%) in the PEN group and 14 patients (70%) in the control group 
developed endoscopic recurrence by 12 months after surgery (P = 0.027) [85].
In 2013 the same authors published an extension study on the long-term efficacy 
of PEN as a maintenance therapy in CD patients who underwent surgery. Twenty 
patients were on PEN, delivered as a continuous elemental enteral formula during 
the night-time, and on a low-fat diet during the day. Twenty control group CD 
patients were given an unrestricted diet without therapy until disease recurrence. 
Recurrence rates after 5-year-follow-up were significantly lower in the PEN group 
compared to the control group (P = 0.02). This study confirmed the results of the 
previous study and showed that PEN may be effective in maintaining remission in 
CD patients after surgery [44]. However, both studies included a small number of 
patients and only the highly compliant ones were assigned to PEN group, so the risk 
of bias was high.
3.2.3 PEN for maintenance therapy in paediatric CD patients
In 1982 Navarro et al. [86] first reported the use of prolonged constant rate 
elemental enteral nutrition (CREN) in CD. It has been used in 17 paediatric patients 
with CD. Exclusive CREN was maintained from 2 to 7 months and progressively 
reduced to assure fractioned oral intakes from 12 to 22 months. From this prelimi-
nary study, CREN appeared to be as effective as CS therapy in initiating remission 
of active CD and was able to supress CS dependence. In some cases, with prolonged 
CREN, reduction or disappearance of stenotic lesions of the bowel was observed. 
Two other positive points must be emphasised: the favourable psychological impact 
of the method and the ability to avoid growth suppression secondary to CS. The 
long-term effects and longer remission must be confirmed by a multicentre study in 
a larger group of patients [86].
In 1988 Belli et al. [87] demonstrated decreased activity of CD and improvement 
in growth in a group of 8 children who had received elemental enteral formula at 
cyclical periods of time (one out of 4 months) for 1 year [87]. Although this was 
a small study, it encouraged further investigations on maintenance therapy with 
enteral nutrition.
Wilschanski et al. [45] conducted a retrospective study on 47 children and 
adolescents with CD who achieved clinical remission after EEN induction therapy. 
Twenty-eight patients continued with nocturnal PEN through a nasogastric tube 
and 19 patients consumed an unrestricted diet without enteral supplementation. 
The relapse rate was significantly higher in patients on an unrestricted diet in 
comparison with those who were treated with PEN at 6 (P < 0.001) and 12 months 
(P < 0.02), respectively. Furthermore, the group of patients on nocturnal PEN who 
had not yet completed puberty had improved linear growth compared to similar 
patients who were on an unrestricted diet [45].
On the contrary, Knight et al. [46] did not confirm the better outcome in 
patients receiving PEN. They retrospectively studied the short and long-term 
outcomes of using enteral nutrition for induction and maintenance of remission 
in paediatric CD patients. Out of 79 newly diagnosed CD patients, 44 (55%) chose 
EEN as the primary induction therapy and 40 (90%) of those responded to treat-
ment. These 40 patients were then encouraged to continue with maintenance PEN 
(1000 ml of elemental or polymeric enteral formula daily) in addition to an unre-
stricted diet, but only 22 (55%) were able to accept the PEN treatment protocol. 
The authors did not find a statistically significant difference in the remission rates 
between the two groups [46]. However, the consumed volume of enteral formula 
was not carefully recorded, this could have affected the results and may have led to 
the higher rate of treatment failure [46].
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A study by Duncan et al. [47] showed completely opposite results. In this 
retrospective study, 48 CD patients who entered clinical remission or responded 
to an eight-week treatment with EEN, were encouraged to continue a maintenance 
therapy with 25% of the volume of the previously used elemental or polymeric 
enteral formula. Only 15 out of 48 (31%) patients chose PEN, for a mean time of 
11 months (range 4–14 months). Twenty (42%) patients took azathioprine and 13 
(27%) patients had no maintenance treatment. Remission rates at one year were 
60% in the PEN group, 65% in the azathioprine group and 15% in the control 
group. There was a significantly higher remission rate in the PEN group versus the 
control group (P = 0.001). Furthermore, remission rates between PEN and azathio-
prine group were not significantly different (P = 0.14) [47].
In 2015 Konno et al. [88], reported their real-life data on the long-term outcome 
of maintenance treatment with PEN in a consecutive cohort of 58 paediatric CD 
patients who entered remission with different treatment regimens. All 58 patients 
received PEN with a least 30 kcal/kg/day of elemental enteral formula in conjunc-
tion with a low-fat diet (< 20 g fat/day). In addition, they were treated only with 
5-ASA, until first relapse. Fifty-two out of 58 patients took enteral formula orally 
and the remaining 6 through a nasogastric tube. The relapse rates were 12% at 
1 year, 27% at 2 years, and 48% at 5 years, respectively [88]. This study surprisingly 
showed that approximately half of the children who received PEN as a maintenance 
therapy were able to sustain remission for 5 years without taking other medication 
such as immunosuppressives.
Schulman et al. [89] studied 42 CD paediatric patients who entered clinical 
remission after EEN and received PEN as a supplementary diet (50% of daily 
energy requirements as polymeric enteral formula). The control group consisted of 
patients who refused PEN. They found that the total increase in body mass index 
(BMI) and the total decrease in the mean weighted Paediatric Crohn’s Disease 
Activity Index between the time of diagnosis and eight months after diagnosis were 
greater in the PEN group compared to the control group. Furthermore, in the PEN 
group there was better improvement in albumin and CRP levels in comparison with 
the control group. However, more than 50% of patients required concomitant main-
tenance therapy within two weeks of PEN initiation and most of patients required 
concomitant immunosuppressive therapy at some point after initiation of PEN [89].
Gavin et al. [48], reported real-life data on their experience with EEN as induc-
tion therapy and PEN as a maintenance therapy. 102 newly diagnosed paediatric CD 
patients were included. Seventy-seven (75%) patients were treated with a 6–8-week 
course of EEN and the remaining 25 with CS (25%). The remission rate in the EEN 
group was 76% and in the CS group 75% respectively. Following induction treat-
ment, 58 out of 102 (57%) patients received PEN as a maintenance therapy (median 
30% of daily energy needs; range from 13 to 65% of daily energy requirements 
of polymeric or elemental formula) and rest as an unrestricted diet. Forty-four 
out of 102 (43%) patients consumed an unrestricted diet for a median duration 
of 4 months (range 1–12 months). The increase of BMI z-score was significantly 
higher in the PEN group in comparison with the unrestricted diet group. However, 
relapse rates were similar in both groups at 6 and 12 months [48].
El-Matary et al. [90], published a systematic review on the efficacy of mainte-
nance PEN. Databases were searched to April 2015. Twelve studies met the inclusion 
criteria; however, a meta-analysis was not performed due to the excessive hetero-
geneity of the studies. Out of these 12 studies, 11 of them had shown a beneficial 
effect of PEN in maintaining remission, therefore, authors concluded that PEN was 
more effective than unrestricted diet in maintaining CD remission [90].
Gavin et al. [91] conduct a survey including patients, parents and UK dietitians 
regarding their experience with maintenance enteral nutrition (MEN) which is 
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often routinely used in paediatric CD to prolong remission although there is limited 
evidence for efficacy and a lack of formal guidelines. They identified a different 
perspective between patients, families and professionals on the use of MEN. Young 
people and parents reported difficulties with adherence to MEN especially due to 
the taste and they stated a preference for dietary advice. This study advocates that 
the extensive use of MEN in clinical practice is limited to comply with ESPGHAN 
recommendations. Patient led care promotes the use of dietary advice as a mode of 
nutritional support during inactive disease [91].
In Kim et al. study [92], they determine the abilities of EEN and PEN to induce 
and maintain clinical remission in paediatric patients with CD, respectively. All 
paediatric patients with CD who received EEN at a single centre in 2000–2014 were 
identified retrospectively. Remission rates of the EEN and PEN during the 2 years 
study period were determined. Risk factors for EEN and PEN failure were also 
identified. They conclude that EEN and PEN effectively induced and maintained 
remission in a paediatric population. However, non-adherence was a limiting factor 
in the success of therapy, especially in females [92].
In Watanabe et al. [93], they investigate the effectiveness of enteral nutrition 
with an elemental diet regarding the avoidance of hospitalisation. Altogether 268 
patients with CD who visited hospital from 2003 to 2008 were enrolled. The rela-
tionship between the proportion of energy consumed with an elemental diet and 
hospitalisation as an endpoint was examined retrospectively. They conclude that the 
use of an elemental diet of 900 kcal/day may be effective in avoiding hospitalisation 
in CD patients with ileal lesions. However, this diet may be useful in improving the 
long-term convalescence of these patients [93].
According to the current ECCO/ESPGHAN clinical guidelines on CD, in chil-
dren with low-risk CD who achieved clinical remission, monotherapy with main-
tenance enteral nutrition (at least 50% of daily energy requirements) can prolong 
remission [22].
4. Conclusions
Despite the evidence that EEN is an effective and safe therapeutic option in 
inducing remission in paediatric and potentially in adult active CD and it is sub-
stantially more effective in promoting mucosal healing compared to CS, it is still 
underused in clinical practice. Its biggest disadvantage is patients’ compliance. 
Taste fatigue due to the poor palatability and the subsequent negative impact on the 
quality of life remain the most important reasons why EEN therapy is not accept-
able to many patients. Thus, the use of PEN, where some ordinary food, besides 
enteral formulas, can be consumed, is rapidly becoming an interesting therapeutic 
option. Unfortunately, the first well designed, prospective randomised controlled 
trial on PEN did not confirm PEN efficacy in inducing remission in active CD [52]. 
However, some recent small and retrospective studies pointed to the possible benefi-
cial effect of PEN in active CD. Larger prospective randomised studies are needed to 
examine the possible role of PEN in inducing remission in paediatric and adult CD.
While EEN is not an acceptable therapeutic option for maintenance of CD 
remission in clinical practice, several studies examined the efficacy and the useful-
ness of PEN in maintaining remission in adult and paediatric CD (Table 1). The 
results were conflicting. Most of these studies were non-randomised, with only a 
small number of patients included. However, the results of some recent studies, 
including the Japanese randomised controlled trials with a large enough sample 
size and a sufficiently low risk of bias [67], were promising and indicated that PEN 
might be effective in maintaining CD remission.
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